Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes is a dataset published in ESMO Open (2025). On theSindex it has a DataRank of 0.448, placing it in the top 42% of the data-sharing corpus. It has been cited 11 times, with 9 citing works in its 1-hop citation network.
Ranks in the top 42% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.373
From this paper's citation signal
Citation Network Contribution
0.0750
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
Yale Cancer Center
Grant: P30CA016359
Foundation for the National Institutes of Health
Grant: 1R37CA279822-01
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
US Department of Defense
Grant: KC190128/W81XWH-20-1-0882
US Department of Defense
Grant: KC220016/ HT9425-23-1-0735
Cancer Prevention and Research Institute of Texas
Grant: RR220009
NCI NIH HHS
Grant: R37 CA279822
National Institutes of Health
Grant: 2P50CA101942-16
DF/HCC Kidney Cancer SPORE
National Institutes of Health
Grant: 5P30CA006516-56
Dana-Farber/Harvard Cancer Center
National Institutes of Health
Grant: 2P30CA016359-15
COMPREHENSIVE CANCER CENTER
National Institutes of Health
Harvard Medical School
FWCI
9.09
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals